Description:
Polo-like kinase 1(Plk1) plays an essential role in inhibiting cell proliferation and comes under the family of serine/threonine-protein kinase, which is a particular target for cancer therapy. In some clinical studies, Plk1 has been identified as a target for cancer. Currently, so many scientists are developing the Plk1 inhibitors, and they are thinking about working on them. A recent strategy for Plk1 inhibition is the development of small-molecule inhibitors, which will inhibit the Plk1 through the ATP-binding site of the Plk1. Now new generation Plk1 inhibitors being tested clinically, which are targeting the polo box domain. This review highlights the recent progress made in the development of Plk1 inhibitors as anticancer agents.

URL:
http://103.158.96.210:88/web_repository/uploads/ps-27-453.pdf

Type:
Journal

Document:
Diploma III Farmasi

Date:
23-06-2024

Author:
Ramesh Sawant